Chlamydia vaccine - AEterna Zentaris/Julius-Maximilians University
Alternative Names: Chlamydia trachomatis vaccine - Aeterna Zentaris/Julius-Maximilians UniversityLatest Information Update: 19 Jan 2023
At a glance
- Originator Julius-Maximilians University
- Developer AEterna Zentaris GmbH; Julius-Maximilians University
- Class Attenuated vaccines; Bacterial vaccines; Peptide vaccines; Synthetic vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Chlamydial infections
Most Recent Events
- 17 Jan 2023 AEterna Zentaris terminates its licence agreement and research contract with Julius-Maximilians-University Wuerzburg
- 17 Jan 2023 Discontinued - Preclinical for Chlamydial infections (Prevention) in Germany (PO)
- 30 Sep 2021 Chlamydia vaccine licensed to AEterna Zentaris for the prevention of Chlamydial infections